Case number 1:23-cv-00788
Teva Pharmaceuticals International GmbH et al v. BendaRx USA Corp > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Mar 27, 2024 | 75 | ORDER granting 73 Joint MOTION to Transfer Case (see Order for further details). Signed by District Judge Rossie D. Alston, Jr on 3/27/2024. (swil) (Entered: 03/28/2024) (1) |
| Mar 26, 2024 | 73 | Joint MOTION to Transfer Case by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Proposed Order Proposed Order)(Eckstein, Maya) (Entered: 03/26/2024) () (3) |
| Mar 26, 2024 | 74 | Memorandum in Support re 73 Joint MOTION to Transfer Case filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Eckstein, Maya) (Entered: 03/26/2024) (4) |
| Mar 26, 2024 | 73 | Joint MOTION to Transfer Case by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Proposed Order Proposed Order)(Eckstein, Maya) (Entered: 03/26/2024) (Proposed Order Proposed Order) (1) |
| Mar 19, 2024 | 72 | STATUS REPORT by Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Eckstein, Maya) (Entered: 03/19/2024) (4) |
| Mar 13, 2024 | 71 | It is hereby ORDERED that the parties Motion for Extension of Time is granted. The Parties' Joint Status Report shall be due no later than March 19, 2024 re 70 Motion for Extension of Time to File. Signed by District Judge Rossie D. Alston, Jr on 3/13/2024. (Sbro) (Entered: 03/13/2024) (1) |
| Mar 12, 2024 | 70 | MOTION for Extension of Time to Submit Joint Status Report by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Proposed Order Order)(Eckstein, Maya) (Entered: 03/12/2024) () (4) |
| Mar 12, 2024 | 70 | MOTION for Extension of Time to Submit Joint Status Report by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Proposed Order Order)(Eckstein, Maya) (Entered: 03/12/2024) (Proposed Order Order) (1) |
| Jan 12, 2024 | 69 | STATUS REPORT Joint Status Report by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Eckstein, Maya) (Entered: 01/12/2024) (4) |
| Nov 13, 2023 | 68 | STATUS REPORT Joint Status Report by BendaRx USA Corp. (Bagley, Andrew) (Entered: 11/13/2023) (4) |
| Sep 14, 2023 | 67 | STATUS REPORT Joint Status Report by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Eckstein, Maya) (Entered: 09/14/2023) (4) |
| Aug 29, 2023 | 66 | ORDERED that the parties' respective Motions to Seal Exhibit B to Plaintiffs' Memorandum (Dkts. 24, 64) are GRANTED and the redacted portions of Exhibit B shall remain permanently under seal; it is further ORDERED that Plaintiff's Motion to Seal Exhibit A is deemed WITHDRAWN (see Order for further details). Signed by Magistrate Judge William E. Fitzpatrick on 8/29/2023. (Dest) (Entered: 08/29/2023) (2) |
| Aug 21, 2023 | 63 | Notice of Filing Sealing Motion LCvR5(C) by BendaRx USA Corp re 23 Memorandum in Support,, portions of Exhibit B (Pond, Joshua) (Entered: 08/21/2023) (3) |
| Aug 21, 2023 | 64 | MOTION to Seal by BendaRx USA Corp. (Attachments: # 1 Proposed Order)(Pond, Joshua) (Entered: 08/21/2023) () (3) |
| Aug 21, 2023 | 65 | RESPONSE to Motion re 24 MOTION to Seal Exhibits A and B to Motion to Stay (Defendant's Supplemental Response) filed by BendaRx USA Corp. (Attachments: # 1 Exhibit A, # 2 Exhibit B (redacted))(Pond, Joshua) (Entered: 08/21/2023) () (5) |
| Aug 21, 2023 | 65 | RESPONSE to Motion re 24 MOTION to Seal Exhibits A and B to Motion to Stay (Defendant's Supplemental Response) filed by BendaRx USA Corp. (Attachments: # 1 Exhibit A, # 2 Exhibit B (redacted))(Pond, Joshua) (Entered: 08/21/2023) (Exhibit A) (7) |
| Aug 21, 2023 | 65 | RESPONSE to Motion re 24 MOTION to Seal Exhibits A and B to Motion to Stay (Defendant's Supplemental Response) filed by BendaRx USA Corp. (Attachments: # 1 Exhibit A, # 2 Exhibit B (redacted))(Pond, Joshua) (Entered: 08/21/2023) (Exhibit B (redacted)) (30) |
| Aug 21, 2023 | 64 | MOTION to Seal by BendaRx USA Corp. (Attachments: # 1 Proposed Order)(Pond, Joshua) (Entered: 08/21/2023) (Proposed Order) (2) |
| Aug 14, 2023 | 62 | ORDERED that the Consent Motion for Extension of Time to File a Response to Motion to Seal 60 is DISMISSED as moot; it is further ORDERED that Defendant shall file further argument in support of the Motion to Seal 24 , consistent with the requirements of Local Civil Rule 5(C), within seven (7) days of entry of this Order and, if appropriate, an updated redacted version of Exhibit B; it is further ORDERED that Defendant shall file a publicly available version of Exhibit A; it is further ORDERED that Exhibit B shall remain sealed pending a determination by the Court on the Motion to Seal. Signed by Magistrate Judge William E. Fitzpatrick on 8/14/2023. (tran, ) (Entered: 08/15/2023) (3) |
| Aug 2, 2023 | 60 | Consent MOTION for Extension of Time to File Response/Reply as to 24 MOTION to Seal Exhibits A and B to Motion to Stay by BendaRx USA Corp. (Attachments: # 1 Proposed Order)(Pond, Joshua) (Entered: 08/02/2023) () (3) |
| Aug 2, 2023 | 61 | RESPONSE to Motion re 24 MOTION to Seal Exhibits A and B to Motion to Stay filed by BendaRx USA Corp. (Attachments: # 1 Exhibit B (Redacted), # 2 Proposed Order)(Pond, Joshua) (Entered: 08/02/2023) () (4) |
| Aug 2, 2023 | 61 | RESPONSE to Motion re 24 MOTION to Seal Exhibits A and B to Motion to Stay filed by BendaRx USA Corp. (Attachments: # 1 Exhibit B (Redacted), # 2 Proposed Order)(Pond, Joshua) (Entered: 08/02/2023) (Exhibit B (Redacted)) (10) |
| Aug 2, 2023 | 61 | RESPONSE to Motion re 24 MOTION to Seal Exhibits A and B to Motion to Stay filed by BendaRx USA Corp. (Attachments: # 1 Exhibit B (Redacted), # 2 Proposed Order)(Pond, Joshua) (Entered: 08/02/2023) (Proposed Order) (1) |
| Aug 2, 2023 | 60 | Consent MOTION for Extension of Time to File Response/Reply as to 24 MOTION to Seal Exhibits A and B to Motion to Stay by BendaRx USA Corp. (Attachments: # 1 Proposed Order)(Pond, Joshua) (Entered: 08/02/2023) (Proposed Order) (1) |
| Jul 21, 2023 | 57 | ORDERED that the parties shall contact the undersigned's chambers within 14 days of the stay being lifted, to schedule a status conference regarding the adoption of a discovery plan and the entry of a discovery order. Signed by Magistrate Judge William E. Fitzpatrick on 7/21/2023. (swil) (Entered: 07/21/2023) (1) |
| Jul 21, 2023 | 58 | ORDER granting 47 Motion to Seal. ORDERED that Dkt. 49 shall remain sealed; it is further ORDERED that Defendant shall submit a response to Plaintiff's Motion to Seal (Dkt. 24), complying with the requirements under Local Civil Rule 7(C), within 7 days of entry of this Order. Signed by Magistrate Judge William E. Fitzpatrick on 07/21/2023. (wgar, ) (Entered: 07/21/2023) (2) |
| Jul 19, 2023 | 55 | ORDER granting 22 Motion to Stay. ORDERED that this matter is STAYED until Final Judgment or order in each of Case Nos. 23-cv-490-CFC (D. Del) and 23-cv-633-CFC (D. Del.). Signed by District Judge Rossie D. Alston, Jr on 07/19/2023. SEE ORDER FOR FURTHER DETAILS. (wgar, ) (Entered: 07/19/2023) (5) |
| Jul 19, 2023 | 59 | Minute Entry for proceedings held before Magistrate Judge William E. Fitzpatrick: Initial Pretrial Conference held on 7/19/2023. Appearance of counsel. Proposed Discovery Plan discussed in open court. Shortly after the IPC, Judge Alston issued an order staying this entire case. Therefore, a Rule 16(b) order will not be issued by Judge Fitzpatrick-per WEF chambers. (Tape #FTR.)(tfitz, ) (Entered: 07/21/2023) (1) |
| Jul 18, 2023 | 56 | ORDER granting 45 Motion for Pro hac vice Appointed Ben Picozzi for Cephalon, LLC,Ben Picozzi for Teva Pharmaceuticals International GmbH. Signed by District Judge Rossie D. Alston, Jr on 7/18/2023. (swil) (Entered: 07/20/2023) (1) |
| Jul 17, 2023 | 53 | NOTICE of Appearance by Joshua B Pond on behalf of BendaRx USA Corp (Pond, Joshua) (Entered: 07/17/2023) (1) |
| Jul 17, 2023 | 54 | Reply to Motion re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit X, # 2 Exhibit Y)(Eckstein, Maya) (Entered: 07/17/2023) () (25) |
| Jul 17, 2023 | 54 | Reply to Motion re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit X, # 2 Exhibit Y)(Eckstein, Maya) (Entered: 07/17/2023) (Exhibit X) (30) |
| Jul 17, 2023 | 54 | Reply to Motion re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit X, # 2 Exhibit Y)(Eckstein, Maya) (Entered: 07/17/2023) (Exhibit Y) (30) |
| Jul 13, 2023 | 52 | NOTICE by BendaRx USA Corp re 46 Memorandum in Opposition, Corrected Exhibit H to Defendant's Opposition to Plaintiffs' Motion to Stay (Bagley, Andrew) (Entered: 07/13/2023) (26) |
| Jul 12, 2023 | 46 | Memorandum in Opposition re 22 MOTION to Stay filed by BendaRx USA Corp. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J)(Bagley, Andrew) (Entered: 07/12/2023) () (22) |
| Jul 12, 2023 | 47 | MOTION to Seal Exhibit B to Opposition to Plaintiffs' Motion to Stay by BendaRx USA Corp. (Attachments: # 1 Proposed Order)(Bagley, Andrew) (Entered: 07/12/2023) () (3) |
| Jul 12, 2023 | 48 | Memorandum in Support re 47 MOTION to Seal Exhibit B to Opposition to Plaintiffs' Motion to Stay filed by BendaRx USA Corp. (Bagley, Andrew) (Entered: 07/12/2023) (4) |
| Jul 12, 2023 | 49 | Sealed Attachment/Exhibit(s) re 47 MOTION to Seal Exhibit B to Opposition to Plaintiffs' Motion to Stay. (Bagley, Andrew) (Entered: 07/12/2023) (0) |
| Jul 12, 2023 | 50 | NOTICE by BendaRx USA Corp re 47 MOTION to Seal Exhibit B to Opposition to Plaintiffs' Motion to Stay (Bagley, Andrew) (Entered: 07/12/2023) (3) |
| Jul 12, 2023 | 51 | Proposed Joint Discovery Plan by Cephalon, LLC, Teva Pharmaceuticals International GmbH.(Eckstein, Maya) (Entered: 07/12/2023) (11) |
| Jul 12, 2023 | 46 | Memorandum in Opposition re 22 MOTION to Stay filed by BendaRx USA Corp. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J)(Bagley, Andrew) (Entered: 07/12/2023) (Exhibit A) (2) |
| Jul 12, 2023 | 46 | Memorandum in Opposition re 22 MOTION to Stay filed by BendaRx USA Corp. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J)(Bagley, Andrew) (Entered: 07/12/2023) (Exhibit B) (1) |
| Jul 12, 2023 | 46 | Memorandum in Opposition re 22 MOTION to Stay filed by BendaRx USA Corp. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J)(Bagley, Andrew) (Entered: 07/12/2023) (Exhibit C) (5) |
| Jul 12, 2023 | 46 | Memorandum in Opposition re 22 MOTION to Stay filed by BendaRx USA Corp. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J)(Bagley, Andrew) (Entered: 07/12/2023) (Exhibit D) (2) |
| Jul 12, 2023 | 46 | Memorandum in Opposition re 22 MOTION to Stay filed by BendaRx USA Corp. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J)(Bagley, Andrew) (Entered: 07/12/2023) (Exhibit E) (30) |
| Jul 12, 2023 | 46 | Memorandum in Opposition re 22 MOTION to Stay filed by BendaRx USA Corp. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J)(Bagley, Andrew) (Entered: 07/12/2023) (Exhibit F) (30) |
| Jul 12, 2023 | 46 | Memorandum in Opposition re 22 MOTION to Stay filed by BendaRx USA Corp. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J)(Bagley, Andrew) (Entered: 07/12/2023) (Exhibit G) (30) |
| Jul 12, 2023 | 46 | Memorandum in Opposition re 22 MOTION to Stay filed by BendaRx USA Corp. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J)(Bagley, Andrew) (Entered: 07/12/2023) (Exhibit H) (3) |
| Jul 12, 2023 | 46 | Memorandum in Opposition re 22 MOTION to Stay filed by BendaRx USA Corp. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J)(Bagley, Andrew) (Entered: 07/12/2023) (Exhibit I) (25) |
| Jul 12, 2023 | 46 | Memorandum in Opposition re 22 MOTION to Stay filed by BendaRx USA Corp. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J)(Bagley, Andrew) (Entered: 07/12/2023) (Exhibit J) (13) |
| Jul 12, 2023 | 47 | MOTION to Seal Exhibit B to Opposition to Plaintiffs' Motion to Stay by BendaRx USA Corp. (Attachments: # 1 Proposed Order)(Bagley, Andrew) (Entered: 07/12/2023) (Proposed Order) (1) |
| Jul 11, 2023 | 45 | Motion to appear Pro Hac Vice by Ben Picozzi and Certification of Local Counsel Maya Eckstein Filing fee $ 75, receipt number AVAEDC-9019245. by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Eckstein, Maya) (Entered: 07/11/2023) (1) |
| Jul 10, 2023 | 44 | ORDERED, that Defendant shall file a brief in response to Plaintiffs' Motion to Stay (ECF Nos. 22, 23) by July 12, 2023, and Plaintiffs shall file a reply brief in support of the Motion to Stay by July 17, 2023 in re 41 Consent MOTION to Expedite Briefing Schedule with Respect to Plaintiffs' Motion to Stay. Signed by Magistrate Judge William E. Fitzpatrick on 7/10/2023. (swil) (Entered: 07/11/2023) (1) |
| Jul 7, 2023 | 41 | Consent MOTION to Expedite Briefing Schedule with Respect to Plaintiffs' Motion to Stay by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Proposed Order Order)(Eckstein, Maya) (Entered: 07/07/2023) () (4) |
| Jul 7, 2023 | 42 | Notice of Hearing Date set for 7/19/2023 re 22 MOTION to Stay , 23 Memorandum in Support,, (Eckstein, Maya) (Entered: 07/07/2023) (3) |
| Jul 7, 2023 | 43 | STIPULATION re 11 Scheduling Order, by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Eckstein, Maya) (Entered: 07/07/2023) (5) |
| Jul 7, 2023 | 41 | Consent MOTION to Expedite Briefing Schedule with Respect to Plaintiffs' Motion to Stay by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Proposed Order Order)(Eckstein, Maya) (Entered: 07/07/2023) (Proposed Order Order) (1) |
| Jul 6, 2023 | 37 | Motion to appear Pro Hac Vice by Shannon Marie Lentz and Certification of Local Counsel Andrew W. Bagley Filing fee $ 75, receipt number AVAEDC-9014003. by BendaRx USA Corp. (Bagley, Andrew) (Entered: 07/06/2023) (3) |
| Jul 6, 2023 | 38 | Motion to appear Pro Hac Vice by Mark Remus and Certification of Local Counsel Andrew W. Bagley Filing fee $ 75, receipt number AVAEDC-9014072. by BendaRx USA Corp. (Bagley, Andrew) (Entered: 07/06/2023) (3) |
| Jul 6, 2023 | 39 | Notice of Under Seal Filing LCvR5 (B) by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH re 24 MOTION to Seal Exhibits A and B to Motion to Stay, 25 Memorandum in Support (Eckstein, Maya) (Entered: 07/06/2023) (3) |
| Jul 6, 2023 | 40 | NOTICE by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH re 27 Notice of Hearing Date Notice of Withdrawal of Notice of Hearing Date (Eckstein, Maya) (Entered: 07/06/2023) (3) |
| Jul 5, 2023 | 22 | MOTION to Stay by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Eckstein, Maya) (Entered: 07/05/2023) (4) |
| Jul 5, 2023 | 23 | Memorandum in Support re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit Ex.A-Under Seal, # 2 Exhibit Ex.B.-Under Seal, # 3 Exhibit Ex.C, # 4 Exhibit Ex.D, # 5 Exhibit Ex.E, # 6 Exhibit Ex.F, # 7 Exhibit Ex.G, # 8 Exhibit Ex.L, # 9 Exhibit Ex.N, # 10 Exhibit Ex.O, # 11 Exhibit Ex.P, # 12 Exhibit Ex.Q, # 13 Exhibit Ex.R, # 14 Exhibit Ex.S, # 15 Exhibit Ex.T, # 16 Exhibit Ex.U, # 17 Exhibit Ex.V, # 18 Exhibit Ex.W)(Eckstein, Maya) (Entered: 07/05/2023) () (24) |
| Jul 5, 2023 | 24 | MOTION to Seal Exhibits A and B to Motion to Stay by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Eckstein, Maya) (Entered: 07/05/2023) (3) |
| Jul 5, 2023 | 25 | Memorandum in Support re 24 MOTION to Seal Exhibits A and B to Motion to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Eckstein, Maya) (Entered: 07/05/2023) (4) |
| Jul 5, 2023 | 26 | Sealed Attachment/Exhibit(s) re 24 MOTION to Seal Exhibits A and B to Motion to Stay. (Attachments: # 1 Exhibit Ex.A, # 2 Exhibit Ex.B)(Eckstein, Maya) (Entered: 07/05/2023) (0) |
| Jul 5, 2023 | 27 | Notice of Hearing Date set for 07/14/2023 re 22 MOTION to Stay , 23 Memorandum in Support,, (Eckstein, Maya) (Entered: 07/05/2023) (3) |
| Jul 5, 2023 | 28 | ORDER denying 13 Motion for Pro hac vice. Signed by District Judge Rossie D. Alston, Jr on 7/5/2023. (swil) (Entered: 07/06/2023) (1) |
| Jul 5, 2023 | 29 | ORDER granting 14 Motion for Pro hac vice Appointed Adam Daniel Harber for Cephalon, LLC,Adam Daniel Harber for Teva Pharmaceuticals International GmbH. Signed by District Judge Rossie D. Alston, Jr on 7/5/2023. (swil) (Entered: 07/06/2023) (1) |
| Jul 5, 2023 | 30 | ORDER granting 15 Motion for Pro hac vice Appointed David Issac Berl for Cephalon, LLC,David Issac Berl for Teva Pharmaceuticals International GmbH. Signed by District Judge Rossie D. Alston, Jr on 7/5/2023. (swil) (Entered: 07/06/2023) (1) |
| Jul 5, 2023 | 31 | ORDER granting 16 Motion for Pro hac vice Appointed Elise Michelle Baumgarten for Cephalon, LLC,Elise Michelle Baumgarten for Teva Pharmaceuticals International GmbH. Signed by District Judge Rossie D. Alston, Jr on 7/5/2023. (swil) (Entered: 07/06/2023) (1) |
| Jul 5, 2023 | 32 | ORDER granting 17 Motion for Pro hac vice Appointed Anne Elise Herold Li for BendaRx USA Corp. Signed by District Judge Rossie D. Alston, Jr on 7/5/2023. (swil) (Entered: 07/06/2023) (1) |
| Jul 5, 2023 | 33 | ORDER granting 18 Motion for Pro hac vice Appointed Daniel Brown for Eagle Pharmaceuticals, Inc. Signed by District Judge Rossie D. Alston, Jr on 7/5/2023. (swil) (Entered: 07/06/2023) (1) |
| Jul 5, 2023 | 34 | ORDER granting 19 Motion for Pro hac vice Appointed Marc Nathan Zubick for Eagle Pharmaceuticals, Inc. Signed by District Judge Rossie D. Alston, Jr on 7/5/2023. (swil) (Entered: 07/06/2023) (1) |
| Jul 5, 2023 | 35 | ORDER granting 20 Motion for Pro hac vice Appointed Alex Grabowski for Eagle Pharmaceuticals, Inc. Signed by District Judge Rossie D. Alston, Jr on 7/5/2023. (swil) (Entered: 07/06/2023) (1) |
| Jul 5, 2023 | 36 | ORDER granting 21 Motion for Pro hac vice Appointed Kenneth Schuler for Eagle Pharmaceuticals, Inc. Signed by District Judge Rossie D. Alston, Jr on 7/5/2023. (swil) (Entered: 07/06/2023) (1) |
| Jul 5, 2023 | 23 | Memorandum in Support re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit Ex.A-Under Seal, # 2 Exhibit Ex.B.-Under Seal, # 3 Exhibit Ex.C, # 4 Exhibit Ex.D, # 5 Exhibit Ex.E, # 6 Exhibit Ex.F, # 7 Exhibit Ex.G, # 8 Exhibit Ex.L, # 9 Exhibit Ex.N, # 10 Exhibit Ex.O, # 11 Exhibit Ex.P, # 12 Exhibit Ex.Q, # 13 Exhibit Ex.R, # 14 Exhibit Ex.S, # 15 Exhibit Ex.T, # 16 Exhibit Ex.U, # 17 Exhibit Ex.V, # 18 Exhibit Ex.W)(Eckstein, Maya) (Entered: 07/05/2023) (Exhibit Ex.A-Under Seal) (1) |
| Jul 5, 2023 | 23 | Memorandum in Support re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit Ex.A-Under Seal, # 2 Exhibit Ex.B.-Under Seal, # 3 Exhibit Ex.C, # 4 Exhibit Ex.D, # 5 Exhibit Ex.E, # 6 Exhibit Ex.F, # 7 Exhibit Ex.G, # 8 Exhibit Ex.L, # 9 Exhibit Ex.N, # 10 Exhibit Ex.O, # 11 Exhibit Ex.P, # 12 Exhibit Ex.Q, # 13 Exhibit Ex.R, # 14 Exhibit Ex.S, # 15 Exhibit Ex.T, # 16 Exhibit Ex.U, # 17 Exhibit Ex.V, # 18 Exhibit Ex.W)(Eckstein, Maya) (Entered: 07/05/2023) (Exhibit Ex.B.-Under Seal) (1) |
| Jul 5, 2023 | 23 | Memorandum in Support re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit Ex.A-Under Seal, # 2 Exhibit Ex.B.-Under Seal, # 3 Exhibit Ex.C, # 4 Exhibit Ex.D, # 5 Exhibit Ex.E, # 6 Exhibit Ex.F, # 7 Exhibit Ex.G, # 8 Exhibit Ex.L, # 9 Exhibit Ex.N, # 10 Exhibit Ex.O, # 11 Exhibit Ex.P, # 12 Exhibit Ex.Q, # 13 Exhibit Ex.R, # 14 Exhibit Ex.S, # 15 Exhibit Ex.T, # 16 Exhibit Ex.U, # 17 Exhibit Ex.V, # 18 Exhibit Ex.W)(Eckstein, Maya) (Entered: 07/05/2023) (Exhibit Ex.C) (30) |
| Jul 5, 2023 | 23 | Memorandum in Support re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit Ex.A-Under Seal, # 2 Exhibit Ex.B.-Under Seal, # 3 Exhibit Ex.C, # 4 Exhibit Ex.D, # 5 Exhibit Ex.E, # 6 Exhibit Ex.F, # 7 Exhibit Ex.G, # 8 Exhibit Ex.L, # 9 Exhibit Ex.N, # 10 Exhibit Ex.O, # 11 Exhibit Ex.P, # 12 Exhibit Ex.Q, # 13 Exhibit Ex.R, # 14 Exhibit Ex.S, # 15 Exhibit Ex.T, # 16 Exhibit Ex.U, # 17 Exhibit Ex.V, # 18 Exhibit Ex.W)(Eckstein, Maya) (Entered: 07/05/2023) (Exhibit Ex.D) (30) |
| Jul 5, 2023 | 23 | Memorandum in Support re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit Ex.A-Under Seal, # 2 Exhibit Ex.B.-Under Seal, # 3 Exhibit Ex.C, # 4 Exhibit Ex.D, # 5 Exhibit Ex.E, # 6 Exhibit Ex.F, # 7 Exhibit Ex.G, # 8 Exhibit Ex.L, # 9 Exhibit Ex.N, # 10 Exhibit Ex.O, # 11 Exhibit Ex.P, # 12 Exhibit Ex.Q, # 13 Exhibit Ex.R, # 14 Exhibit Ex.S, # 15 Exhibit Ex.T, # 16 Exhibit Ex.U, # 17 Exhibit Ex.V, # 18 Exhibit Ex.W)(Eckstein, Maya) (Entered: 07/05/2023) (Exhibit Ex.E) (6) |
| Jul 5, 2023 | 23 | Memorandum in Support re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit Ex.A-Under Seal, # 2 Exhibit Ex.B.-Under Seal, # 3 Exhibit Ex.C, # 4 Exhibit Ex.D, # 5 Exhibit Ex.E, # 6 Exhibit Ex.F, # 7 Exhibit Ex.G, # 8 Exhibit Ex.L, # 9 Exhibit Ex.N, # 10 Exhibit Ex.O, # 11 Exhibit Ex.P, # 12 Exhibit Ex.Q, # 13 Exhibit Ex.R, # 14 Exhibit Ex.S, # 15 Exhibit Ex.T, # 16 Exhibit Ex.U, # 17 Exhibit Ex.V, # 18 Exhibit Ex.W)(Eckstein, Maya) (Entered: 07/05/2023) (Exhibit Ex.F) (6) |
| Jul 5, 2023 | 23 | Memorandum in Support re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit Ex.A-Under Seal, # 2 Exhibit Ex.B.-Under Seal, # 3 Exhibit Ex.C, # 4 Exhibit Ex.D, # 5 Exhibit Ex.E, # 6 Exhibit Ex.F, # 7 Exhibit Ex.G, # 8 Exhibit Ex.L, # 9 Exhibit Ex.N, # 10 Exhibit Ex.O, # 11 Exhibit Ex.P, # 12 Exhibit Ex.Q, # 13 Exhibit Ex.R, # 14 Exhibit Ex.S, # 15 Exhibit Ex.T, # 16 Exhibit Ex.U, # 17 Exhibit Ex.V, # 18 Exhibit Ex.W)(Eckstein, Maya) (Entered: 07/05/2023) (Exhibit Ex.G) (9) |
| Jul 5, 2023 | 23 | Memorandum in Support re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit Ex.A-Under Seal, # 2 Exhibit Ex.B.-Under Seal, # 3 Exhibit Ex.C, # 4 Exhibit Ex.D, # 5 Exhibit Ex.E, # 6 Exhibit Ex.F, # 7 Exhibit Ex.G, # 8 Exhibit Ex.L, # 9 Exhibit Ex.N, # 10 Exhibit Ex.O, # 11 Exhibit Ex.P, # 12 Exhibit Ex.Q, # 13 Exhibit Ex.R, # 14 Exhibit Ex.S, # 15 Exhibit Ex.T, # 16 Exhibit Ex.U, # 17 Exhibit Ex.V, # 18 Exhibit Ex.W)(Eckstein, Maya) (Entered: 07/05/2023) (Exhibit Ex.L) (22) |
| Jul 5, 2023 | 23 | Memorandum in Support re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit Ex.A-Under Seal, # 2 Exhibit Ex.B.-Under Seal, # 3 Exhibit Ex.C, # 4 Exhibit Ex.D, # 5 Exhibit Ex.E, # 6 Exhibit Ex.F, # 7 Exhibit Ex.G, # 8 Exhibit Ex.L, # 9 Exhibit Ex.N, # 10 Exhibit Ex.O, # 11 Exhibit Ex.P, # 12 Exhibit Ex.Q, # 13 Exhibit Ex.R, # 14 Exhibit Ex.S, # 15 Exhibit Ex.T, # 16 Exhibit Ex.U, # 17 Exhibit Ex.V, # 18 Exhibit Ex.W)(Eckstein, Maya) (Entered: 07/05/2023) (Exhibit Ex.N) (2) |
| Jul 5, 2023 | 23 | Memorandum in Support re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit Ex.A-Under Seal, # 2 Exhibit Ex.B.-Under Seal, # 3 Exhibit Ex.C, # 4 Exhibit Ex.D, # 5 Exhibit Ex.E, # 6 Exhibit Ex.F, # 7 Exhibit Ex.G, # 8 Exhibit Ex.L, # 9 Exhibit Ex.N, # 10 Exhibit Ex.O, # 11 Exhibit Ex.P, # 12 Exhibit Ex.Q, # 13 Exhibit Ex.R, # 14 Exhibit Ex.S, # 15 Exhibit Ex.T, # 16 Exhibit Ex.U, # 17 Exhibit Ex.V, # 18 Exhibit Ex.W)(Eckstein, Maya) (Entered: 07/05/2023) (Exhibit Ex.O) (2) |
| Jul 5, 2023 | 23 | Memorandum in Support re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit Ex.A-Under Seal, # 2 Exhibit Ex.B.-Under Seal, # 3 Exhibit Ex.C, # 4 Exhibit Ex.D, # 5 Exhibit Ex.E, # 6 Exhibit Ex.F, # 7 Exhibit Ex.G, # 8 Exhibit Ex.L, # 9 Exhibit Ex.N, # 10 Exhibit Ex.O, # 11 Exhibit Ex.P, # 12 Exhibit Ex.Q, # 13 Exhibit Ex.R, # 14 Exhibit Ex.S, # 15 Exhibit Ex.T, # 16 Exhibit Ex.U, # 17 Exhibit Ex.V, # 18 Exhibit Ex.W)(Eckstein, Maya) (Entered: 07/05/2023) (Exhibit Ex.P) (2) |
| Jul 5, 2023 | 23 | Memorandum in Support re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit Ex.A-Under Seal, # 2 Exhibit Ex.B.-Under Seal, # 3 Exhibit Ex.C, # 4 Exhibit Ex.D, # 5 Exhibit Ex.E, # 6 Exhibit Ex.F, # 7 Exhibit Ex.G, # 8 Exhibit Ex.L, # 9 Exhibit Ex.N, # 10 Exhibit Ex.O, # 11 Exhibit Ex.P, # 12 Exhibit Ex.Q, # 13 Exhibit Ex.R, # 14 Exhibit Ex.S, # 15 Exhibit Ex.T, # 16 Exhibit Ex.U, # 17 Exhibit Ex.V, # 18 Exhibit Ex.W)(Eckstein, Maya) (Entered: 07/05/2023) (Exhibit Ex.Q) (3) |
| Jul 5, 2023 | 23 | Memorandum in Support re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit Ex.A-Under Seal, # 2 Exhibit Ex.B.-Under Seal, # 3 Exhibit Ex.C, # 4 Exhibit Ex.D, # 5 Exhibit Ex.E, # 6 Exhibit Ex.F, # 7 Exhibit Ex.G, # 8 Exhibit Ex.L, # 9 Exhibit Ex.N, # 10 Exhibit Ex.O, # 11 Exhibit Ex.P, # 12 Exhibit Ex.Q, # 13 Exhibit Ex.R, # 14 Exhibit Ex.S, # 15 Exhibit Ex.T, # 16 Exhibit Ex.U, # 17 Exhibit Ex.V, # 18 Exhibit Ex.W)(Eckstein, Maya) (Entered: 07/05/2023) (Exhibit Ex.R) (2) |
| Jul 5, 2023 | 23 | Memorandum in Support re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit Ex.A-Under Seal, # 2 Exhibit Ex.B.-Under Seal, # 3 Exhibit Ex.C, # 4 Exhibit Ex.D, # 5 Exhibit Ex.E, # 6 Exhibit Ex.F, # 7 Exhibit Ex.G, # 8 Exhibit Ex.L, # 9 Exhibit Ex.N, # 10 Exhibit Ex.O, # 11 Exhibit Ex.P, # 12 Exhibit Ex.Q, # 13 Exhibit Ex.R, # 14 Exhibit Ex.S, # 15 Exhibit Ex.T, # 16 Exhibit Ex.U, # 17 Exhibit Ex.V, # 18 Exhibit Ex.W)(Eckstein, Maya) (Entered: 07/05/2023) (Exhibit Ex.S) (5) |
| Jul 5, 2023 | 23 | Memorandum in Support re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit Ex.A-Under Seal, # 2 Exhibit Ex.B.-Under Seal, # 3 Exhibit Ex.C, # 4 Exhibit Ex.D, # 5 Exhibit Ex.E, # 6 Exhibit Ex.F, # 7 Exhibit Ex.G, # 8 Exhibit Ex.L, # 9 Exhibit Ex.N, # 10 Exhibit Ex.O, # 11 Exhibit Ex.P, # 12 Exhibit Ex.Q, # 13 Exhibit Ex.R, # 14 Exhibit Ex.S, # 15 Exhibit Ex.T, # 16 Exhibit Ex.U, # 17 Exhibit Ex.V, # 18 Exhibit Ex.W)(Eckstein, Maya) (Entered: 07/05/2023) (Exhibit Ex.T) (9) |
| Jul 5, 2023 | 23 | Memorandum in Support re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit Ex.A-Under Seal, # 2 Exhibit Ex.B.-Under Seal, # 3 Exhibit Ex.C, # 4 Exhibit Ex.D, # 5 Exhibit Ex.E, # 6 Exhibit Ex.F, # 7 Exhibit Ex.G, # 8 Exhibit Ex.L, # 9 Exhibit Ex.N, # 10 Exhibit Ex.O, # 11 Exhibit Ex.P, # 12 Exhibit Ex.Q, # 13 Exhibit Ex.R, # 14 Exhibit Ex.S, # 15 Exhibit Ex.T, # 16 Exhibit Ex.U, # 17 Exhibit Ex.V, # 18 Exhibit Ex.W)(Eckstein, Maya) (Entered: 07/05/2023) (Exhibit Ex.U) (14) |
| Jul 5, 2023 | 23 | Memorandum in Support re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit Ex.A-Under Seal, # 2 Exhibit Ex.B.-Under Seal, # 3 Exhibit Ex.C, # 4 Exhibit Ex.D, # 5 Exhibit Ex.E, # 6 Exhibit Ex.F, # 7 Exhibit Ex.G, # 8 Exhibit Ex.L, # 9 Exhibit Ex.N, # 10 Exhibit Ex.O, # 11 Exhibit Ex.P, # 12 Exhibit Ex.Q, # 13 Exhibit Ex.R, # 14 Exhibit Ex.S, # 15 Exhibit Ex.T, # 16 Exhibit Ex.U, # 17 Exhibit Ex.V, # 18 Exhibit Ex.W)(Eckstein, Maya) (Entered: 07/05/2023) (Exhibit Ex.V) (7) |
| Jul 5, 2023 | 23 | Memorandum in Support re 22 MOTION to Stay filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit Ex.A-Under Seal, # 2 Exhibit Ex.B.-Under Seal, # 3 Exhibit Ex.C, # 4 Exhibit Ex.D, # 5 Exhibit Ex.E, # 6 Exhibit Ex.F, # 7 Exhibit Ex.G, # 8 Exhibit Ex.L, # 9 Exhibit Ex.N, # 10 Exhibit Ex.O, # 11 Exhibit Ex.P, # 12 Exhibit Ex.Q, # 13 Exhibit Ex.R, # 14 Exhibit Ex.S, # 15 Exhibit Ex.T, # 16 Exhibit Ex.U, # 17 Exhibit Ex.V, # 18 Exhibit Ex.W)(Eckstein, Maya) (Entered: 07/05/2023) (Exhibit Ex.W) (4) |
| Jun 27, 2023 | 18 | Motion to appear Pro Hac Vice by Daniel Brown and Certification of Local Counsel Eden Darrell Filing fee $ 75, receipt number AVAEDC-9000550. by Eagle Pharmaceuticals, Inc.. (Darrell, Eden) (Entered: 06/27/2023) (1) |
| Jun 27, 2023 | 19 | Motion to appear Pro Hac Vice by Marc Zubick and Certification of Local Counsel Eden Darrell Filing fee $ 75, receipt number AVAEDC-9000570. by Eagle Pharmaceuticals, Inc.. (Darrell, Eden) (Entered: 06/27/2023) (1) |
| Jun 27, 2023 | 20 | Motion to appear Pro Hac Vice by Alex Grabowski and Certification of Local Counsel Eden Darrell Filing fee $ 75, receipt number AVAEDC-9000591. by Eagle Pharmaceuticals, Inc.. (Darrell, Eden) (Main Document 20 replaced on 6/29/2023) (wgar, ). (Entered: 06/27/2023) (1) |
| Jun 27, 2023 | 21 | Motion to appear Pro Hac Vice by Kenneth Schuler and Certification of Local Counsel Eden Darrell Filing fee $ 75, receipt number AVAEDC-9000599. by Eagle Pharmaceuticals, Inc.. (Darrell, Eden) (Main Document 21 replaced on 6/29/2023) (wgar, ). (Entered: 06/27/2023) (1) |
| Jun 23, 2023 | 13 | Motion to appear Pro Hac Vice by Ben Picozzi and Certification of Local Counsel Maya Eckstein Filing fee $ 75, receipt number AVAEDC-8995744. by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Eckstein, Maya) (Entered: 06/23/2023) (1) |
| Jun 23, 2023 | 14 | Motion to appear Pro Hac Vice by Adam Harber and Certification of Local Counsel Maya Eckstein Filing fee $ 75, receipt number AVAEDC-8995779. by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Eckstein, Maya) (Entered: 06/23/2023) (1) |
| Jun 23, 2023 | 15 | Motion to appear Pro Hac Vice by David Berl and Certification of Local Counsel Maya Eckstein Filing fee $ 75, receipt number AVAEDC-8995790. by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Eckstein, Maya) (Entered: 06/23/2023) (1) |
| Jun 23, 2023 | 16 | Motion to appear Pro Hac Vice by Elise Baumgarten and Certification of Local Counsel Maya Eckstein Filing fee $ 75, receipt number AVAEDC-8995802. by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Eckstein, Maya) (Entered: 06/23/2023) (1) |
| Jun 23, 2023 | 17 | Motion to appear Pro Hac Vice by Anne Elise Herold Li and Certification of Local Counsel Andrew W. Bagley Filing fee $ 75, receipt number AVAEDC-8995824. by BendaRx USA Corp. (Bagley, Andrew) (Entered: 06/23/2023) (3) |
| Jun 22, 2023 | 11 | SCHEDULING ORDER:Initial Pretrial Conference set for 7/19/2023 at 11:00 AM in Alexandria Courtroom 500 before Magistrate Judge William E. Fitzpatrick.Discovery due by 10/13/2023.Final Pretrial Conference set for 10/19/2023 at 10:00 AM in Alexandria Courtroom 1000 before District Judge Rossie D. Alston Jr. Signed by District Judge Rossie D. Alston, Jr on 06/22/2023. (Attachments: # 1 Magistrate Consent Form, # 2 Pretrial Notice)(tran) (Entered: 06/22/2023) (Main Document) (2) |
| Jun 22, 2023 | 12 | NOTICE of Appearance by Eden Marie Darrell on behalf of Eagle Pharmaceuticals, Inc. (Darrell, Eden) (Entered: 06/22/2023) (1) |
| Jun 22, 2023 | 11 | SCHEDULING ORDER:Initial Pretrial Conference set for 7/19/2023 at 11:00 AM in Alexandria Courtroom 500 before Magistrate Judge William E. Fitzpatrick.Discovery due by 10/13/2023.Final Pretrial Conference set for 10/19/2023 at 10:00 AM in Alexandria Courtroom 1000 before District Judge Rossie D. Alston Jr. Signed by District Judge Rossie D. Alston, Jr on 06/22/2023. (Attachments: # 1 Magistrate Consent Form, # 2 Pretrial Notice)(tran) (Entered: 06/22/2023) (Magistrate Consent Form) (1) |
| Jun 22, 2023 | 11 | SCHEDULING ORDER:Initial Pretrial Conference set for 7/19/2023 at 11:00 AM in Alexandria Courtroom 500 before Magistrate Judge William E. Fitzpatrick.Discovery due by 10/13/2023.Final Pretrial Conference set for 10/19/2023 at 10:00 AM in Alexandria Courtroom 1000 before District Judge Rossie D. Alston Jr. Signed by District Judge Rossie D. Alston, Jr on 06/22/2023. (Attachments: # 1 Magistrate Consent Form, # 2 Pretrial Notice)(tran) (Entered: 06/22/2023) (Pretrial Notice) (1) |
| Jun 21, 2023 | 7 | NOTICE of Appearance by Andrew W. Bagley on behalf of BendaRx USA Corp (Bagley, Andrew) (Entered: 06/21/2023) (1) |
| Jun 21, 2023 | 8 | Financial Interest Disclosure Statement (Local Rule 7.1) by BendaRx USA Corp. (Bagley, Andrew) (Entered: 06/21/2023) (4) |
| Jun 21, 2023 | 9 | ANSWER to Complaint by BendaRx USA Corp.(Bagley, Andrew) (Entered: 06/21/2023) (29) |
| Jun 21, 2023 | 10 | Report on the filing or determination of an action regarding patent and/or trademark. (jlan) (Entered: 06/21/2023) (3) |
| Jun 20, 2023 | 5 | Summons Issued as to BendaRx USA Corp, NOTICE TO ATTORNEY: Please remove the headers and print two duplexed copies of the electronically issued summons for each Defendant. Please serve one copy of the summons and a copy of the Complaint upon each Defendant. Please ensure that your process server returns the service copy (executed or unexecuted) to your attention and electronically file it using the filing events, Summons Returned Executed or Summons Returned Unexecuted. (Attachments: # 1 Notice to Attorney)(Sbro) (Entered: 06/20/2023) (Main Document) (2) |
| Jun 20, 2023 | 6 | NOTICE by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH re 1 Complaint, Report onthe filing or Determination of an Action regarding a Patent or Trademark (Eckstein, Maya) (Entered: 06/20/2023) (3) |
| Jun 20, 2023 | 5 | Summons Issued as to BendaRx USA Corp, NOTICE TO ATTORNEY: Please remove the headers and print two duplexed copies of the electronically issued summons for each Defendant. Please serve one copy of the summons and a copy of the Complaint upon each Defendant. Please ensure that your process server returns the service copy (executed or unexecuted) to your attention and electronically file it using the filing events, Summons Returned Executed or Summons Returned Unexecuted. (Attachments: # 1 Notice to Attorney)(Sbro) (Entered: 06/20/2023) (Notice to Attorney) (1) |
| Jun 16, 2023 | 1 | Complaint ( Filing fee $ 402, receipt number AVAEDC-8986443.), filed by Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc., Cephalon, LLC. (Attachments: # 1 Civil Cover Sheet Civil Cover Sheet, # 2 Exhibit Ex.A, # 3 Exhibit Ex.B, # 4 Exhibit Ex.C, # 5 Exhibit Ex.D, # 6 Exhibit Ex.E, # 7 Exhibit Ex.F, # 8 Exhibit Ex.G, # 9 Exhibit Ex.H, # 10 Exhibit Ex.I, # 11 Exhibit Ex.J, # 12 Exhibit Ex.K)(Eckstein, Maya) (Entered: 06/16/2023) (Main Document) (30) |
| Jun 16, 2023 | 2 | Financial Interest Disclosure Statement (Local Rule 7.1) by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Eckstein, Maya) (Entered: 06/16/2023) (3) |
| Jun 16, 2023 | 3 | Proposed Summons re 1 Complaint, by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Eckstein, Maya) (Main Document 3 replaced to correct summons on 6/20/2023) (Sbro). (Entered: 06/16/2023) (2) |
| Jun 16, 2023 | 4 | Corporate Disclosure Statement by Eagle Pharmaceuticals, Inc.. (Darrell, Eden) (Entered: 06/16/2023) (3) |
| Jun 16, 2023 | N/A | Initial Case Assignment to District Judge Rossie D. Alston, Jr and Magistrate Judge William E. Fitzpatrick. (Sbro) (Entered: 06/20/2023) (0) |
| Jun 16, 2023 | 1 | Complaint ( Filing fee $ 402, receipt number AVAEDC-8986443.), filed by Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc., Cephalon, LLC. (Attachments: # 1 Civil Cover Sheet Civil Cover Sheet, # 2 Exhibit Ex.A, # 3 Exhibit Ex.B, # 4 Exhibit Ex.C, # 5 Exhibit Ex.D, # 6 Exhibit Ex.E, # 7 Exhibit Ex.F, # 8 Exhibit Ex.G, # 9 Exhibit Ex.H, # 10 Exhibit Ex.I, # 11 Exhibit Ex.J, # 12 Exhibit Ex.K)(Eckstein, Maya) (Entered: 06/16/2023) (Civil Cover Sheet Civil Cover Sheet) (3) |
| Jun 16, 2023 | 1 | Complaint ( Filing fee $ 402, receipt number AVAEDC-8986443.), filed by Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc., Cephalon, LLC. (Attachments: # 1 Civil Cover Sheet Civil Cover Sheet, # 2 Exhibit Ex.A, # 3 Exhibit Ex.B, # 4 Exhibit Ex.C, # 5 Exhibit Ex.D, # 6 Exhibit Ex.E, # 7 Exhibit Ex.F, # 8 Exhibit Ex.G, # 9 Exhibit Ex.H, # 10 Exhibit Ex.I, # 11 Exhibit Ex.J, # 12 Exhibit Ex.K)(Eckstein, Maya) (Entered: 06/16/2023) (Exhibit Ex.A) (26) |
| Jun 16, 2023 | 1 | Complaint ( Filing fee $ 402, receipt number AVAEDC-8986443.), filed by Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc., Cephalon, LLC. (Attachments: # 1 Civil Cover Sheet Civil Cover Sheet, # 2 Exhibit Ex.A, # 3 Exhibit Ex.B, # 4 Exhibit Ex.C, # 5 Exhibit Ex.D, # 6 Exhibit Ex.E, # 7 Exhibit Ex.F, # 8 Exhibit Ex.G, # 9 Exhibit Ex.H, # 10 Exhibit Ex.I, # 11 Exhibit Ex.J, # 12 Exhibit Ex.K)(Eckstein, Maya) (Entered: 06/16/2023) (Exhibit Ex.B) (30) |
| Jun 16, 2023 | 1 | Complaint ( Filing fee $ 402, receipt number AVAEDC-8986443.), filed by Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc., Cephalon, LLC. (Attachments: # 1 Civil Cover Sheet Civil Cover Sheet, # 2 Exhibit Ex.A, # 3 Exhibit Ex.B, # 4 Exhibit Ex.C, # 5 Exhibit Ex.D, # 6 Exhibit Ex.E, # 7 Exhibit Ex.F, # 8 Exhibit Ex.G, # 9 Exhibit Ex.H, # 10 Exhibit Ex.I, # 11 Exhibit Ex.J, # 12 Exhibit Ex.K)(Eckstein, Maya) (Entered: 06/16/2023) (Exhibit Ex.C) (28) |
| Jun 16, 2023 | 1 | Complaint ( Filing fee $ 402, receipt number AVAEDC-8986443.), filed by Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc., Cephalon, LLC. (Attachments: # 1 Civil Cover Sheet Civil Cover Sheet, # 2 Exhibit Ex.A, # 3 Exhibit Ex.B, # 4 Exhibit Ex.C, # 5 Exhibit Ex.D, # 6 Exhibit Ex.E, # 7 Exhibit Ex.F, # 8 Exhibit Ex.G, # 9 Exhibit Ex.H, # 10 Exhibit Ex.I, # 11 Exhibit Ex.J, # 12 Exhibit Ex.K)(Eckstein, Maya) (Entered: 06/16/2023) (Exhibit Ex.D) (30) |
| Jun 16, 2023 | 1 | Complaint ( Filing fee $ 402, receipt number AVAEDC-8986443.), filed by Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc., Cephalon, LLC. (Attachments: # 1 Civil Cover Sheet Civil Cover Sheet, # 2 Exhibit Ex.A, # 3 Exhibit Ex.B, # 4 Exhibit Ex.C, # 5 Exhibit Ex.D, # 6 Exhibit Ex.E, # 7 Exhibit Ex.F, # 8 Exhibit Ex.G, # 9 Exhibit Ex.H, # 10 Exhibit Ex.I, # 11 Exhibit Ex.J, # 12 Exhibit Ex.K)(Eckstein, Maya) (Entered: 06/16/2023) (Exhibit Ex.E) (29) |
| Jun 16, 2023 | 1 | Complaint ( Filing fee $ 402, receipt number AVAEDC-8986443.), filed by Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc., Cephalon, LLC. (Attachments: # 1 Civil Cover Sheet Civil Cover Sheet, # 2 Exhibit Ex.A, # 3 Exhibit Ex.B, # 4 Exhibit Ex.C, # 5 Exhibit Ex.D, # 6 Exhibit Ex.E, # 7 Exhibit Ex.F, # 8 Exhibit Ex.G, # 9 Exhibit Ex.H, # 10 Exhibit Ex.I, # 11 Exhibit Ex.J, # 12 Exhibit Ex.K)(Eckstein, Maya) (Entered: 06/16/2023) (Exhibit Ex.F) (30) |
| Jun 16, 2023 | 1 | Complaint ( Filing fee $ 402, receipt number AVAEDC-8986443.), filed by Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc., Cephalon, LLC. (Attachments: # 1 Civil Cover Sheet Civil Cover Sheet, # 2 Exhibit Ex.A, # 3 Exhibit Ex.B, # 4 Exhibit Ex.C, # 5 Exhibit Ex.D, # 6 Exhibit Ex.E, # 7 Exhibit Ex.F, # 8 Exhibit Ex.G, # 9 Exhibit Ex.H, # 10 Exhibit Ex.I, # 11 Exhibit Ex.J, # 12 Exhibit Ex.K)(Eckstein, Maya) (Entered: 06/16/2023) (Exhibit Ex.G) (28) |
| Jun 16, 2023 | 1 | Complaint ( Filing fee $ 402, receipt number AVAEDC-8986443.), filed by Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc., Cephalon, LLC. (Attachments: # 1 Civil Cover Sheet Civil Cover Sheet, # 2 Exhibit Ex.A, # 3 Exhibit Ex.B, # 4 Exhibit Ex.C, # 5 Exhibit Ex.D, # 6 Exhibit Ex.E, # 7 Exhibit Ex.F, # 8 Exhibit Ex.G, # 9 Exhibit Ex.H, # 10 Exhibit Ex.I, # 11 Exhibit Ex.J, # 12 Exhibit Ex.K)(Eckstein, Maya) (Entered: 06/16/2023) (Exhibit Ex.H) (30) |
| Jun 16, 2023 | 1 | Complaint ( Filing fee $ 402, receipt number AVAEDC-8986443.), filed by Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc., Cephalon, LLC. (Attachments: # 1 Civil Cover Sheet Civil Cover Sheet, # 2 Exhibit Ex.A, # 3 Exhibit Ex.B, # 4 Exhibit Ex.C, # 5 Exhibit Ex.D, # 6 Exhibit Ex.E, # 7 Exhibit Ex.F, # 8 Exhibit Ex.G, # 9 Exhibit Ex.H, # 10 Exhibit Ex.I, # 11 Exhibit Ex.J, # 12 Exhibit Ex.K)(Eckstein, Maya) (Entered: 06/16/2023) (Exhibit Ex.I) (18) |
| Jun 16, 2023 | 1 | Complaint ( Filing fee $ 402, receipt number AVAEDC-8986443.), filed by Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc., Cephalon, LLC. (Attachments: # 1 Civil Cover Sheet Civil Cover Sheet, # 2 Exhibit Ex.A, # 3 Exhibit Ex.B, # 4 Exhibit Ex.C, # 5 Exhibit Ex.D, # 6 Exhibit Ex.E, # 7 Exhibit Ex.F, # 8 Exhibit Ex.G, # 9 Exhibit Ex.H, # 10 Exhibit Ex.I, # 11 Exhibit Ex.J, # 12 Exhibit Ex.K)(Eckstein, Maya) (Entered: 06/16/2023) (Exhibit Ex.J) (30) |
| Jun 16, 2023 | 1 | Complaint ( Filing fee $ 402, receipt number AVAEDC-8986443.), filed by Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc., Cephalon, LLC. (Attachments: # 1 Civil Cover Sheet Civil Cover Sheet, # 2 Exhibit Ex.A, # 3 Exhibit Ex.B, # 4 Exhibit Ex.C, # 5 Exhibit Ex.D, # 6 Exhibit Ex.E, # 7 Exhibit Ex.F, # 8 Exhibit Ex.G, # 9 Exhibit Ex.H, # 10 Exhibit Ex.I, # 11 Exhibit Ex.J, # 12 Exhibit Ex.K)(Eckstein, Maya) (Entered: 06/16/2023) (Exhibit Ex.K) (28) |
